Proliferation and cell fate determination in the developing embryo are extrinsically regulated by multiple interactions among diverse secreted factors, such as Sonic Hedgehog (SHh), which act in a concentration-dependent manner. The fact that SHh is secreted as a lipidmodifi ed protein suggests the existence of a mechanism to regulate its movement across embryonic fi elds. We have previously shown that heparan sulfate proteoglycans (HSPGs) are required for SHh binding and signalling. However, it was not determined which specifi c HSPG was responsible for these functions. Here we evaluated the contribution of perlecan on SHh localization and activity. To understand the mechanism of action of perlecan at the cellular level, we studied the role of perlecan-SHh interaction in SHh activity using both cell culture and biochemical assays. Our fi ndings show that perlecan is a crucial anchor and modulator of SHh activity acting as an extracellular positive regulator of SHh.
INTRODUCTION
Differentiating cells undergo developmentally regulated changes in cell-cell and cell-matrix adhesion that control proliferation, differentiation and migration through microenvironments. The diversity of HSPGs expression patterns, coupled with their interactions with the extracellular matrix (ECM), cell adhesion molecules and growth factors during development, has emphasized their critical importance in the regulation of these events. Classical biochemical and cell culture assays have implicated HSPGs as modulators of growth factor activity; they bind through its HS chains to a variety of growth factors and regulate their ability to signal (Carey, 1997; Larraín et al., 1998; Bernfi eld et al., 1999) . Perlecan is one of the most ubiquitous and multifunctional ECM proteins. Genetic analyses have uncovered a role for perlecan in mediating hedgehog (Hh) and fi broblast growth factor (FGF) signaling both in vertebrates and invertebrates (Park et al., 2003; Giros et al., 2007) .
Sonic hedgehog (SHh) belongs to the hedgehog (Hh) family proteins. These are secreted proteins that act as morphogens, controlling embryonic development and tissue homeostasis (Ingham and McMahon, 2001 , Riobo and Manning, 2007 , Komada et al., 2008 . In addition to the role of SHH during development, SHH activity needs to be tightly regulated during adulthood, since its aberrant activation is reported to predispose to malignant types of tumors in different organs (Clement et al., 2007, Stecca and Ruiz i Altaba, 2009) .
Hh proteins are synthesized as a 45-kDa precursors, that are auto-catalytically processed in N-terminal (Hh-N) and C-terminal (Hh-C) fragments (Lee et al., 1994) . The Hh-N fragment suffers two lipidic modifications that restrict its free diffusion and facilitate transport and signaling (Mann and Beachy, 2004) . First, and together with auto-processing, a cholesterol moiety is covalently attached to the C-terminus of the Hh-N fragment (Porter et al., 1996) and then a palmitate groups is added to its N-terminus (Pepinsky et al., 1998) producing a fully processed and active Hh molecule (Hh-Np). Cellular responses to Hh are mediated by the Hh-binding receptor patched1 (Ptc1) and the cell-surface transducer smoothened (Smo). In the absence of Hh, Smo is inactive, probably because it localizes to internal membranes. After Hh binding to Ptc, Smo is relocated to the cell surface and becomes active (Ingham and McMahon, 2001; Zhu et al., 2003) . Once activated, Smo induces a complex series of intracellular reactions that target the Gli family of transcription factors and culminates in the activation of Hh-specifi c targets such as Ptc1, Gli1, n-myc among others (Ingham and McMahon, 2001 , for review see Ruiz i Altaba et al., 2003) .
Hh tissue spreading is controlled not only by lipid modifi cations but also by cell surface Hh-binding molecules and proteoglycans in the extracellular space. Even though the role of HSPG in the Hh pathway have been interpreted as an effect on diffusion recent results clearly indicate that they are required for proper Hh signalling in embryonic epidermis (Desbordes and Sanson, 2003) and in cell culture assays (Lum et al., 2003) . Analysis of Perlecan loss of function in mice shed new light on its role during development. Perlecan knockout mice show hypoplastic tissue and abnormal patterning in the embryonic brain. Perlecan is expressed in the basal lamina of the developing neuroepithelium and most perlecan null embryos (Costell et al., 1999) exhibit exencephaly. Interestingly, perlecan seems to be required to concentrate SHh signalling in the developing brain (Giros et al., 2007) .
How does perlecan affect SHh function? Does it simply sequester it or does it act through an interaction with the receptor complex? To further understand the mechanism by which perlecan regulates SHh activity at the cellular level, we decided to evaluate the functional importance of this interaction using cell culture and biochemical assays. In order to elucidate perlecan-SHh interaction on a large scale, a multipotent mesodermal cell line (C3H10T1/2 clone 8, hereafter referred to as 10T1/2; Reznikoff et al., 1973) was employed as a model system. This line has been widely studied in regard to its responsiveness to Hh proteins Nakamura et al., 1997; Pathi et al., 2001) . Importantly, perlecan has been shown to strongly induce chondrogenic differentiation in these cells (French et al., 1999) . To directly address the role of perlecan we also used perlecan null embryonic fi broblasts (Costell et al., 1999) . This study was further complemented by analyzing the effects of perlecan-SHh interactions in a developmental context evaluating perlecan interaction with SHh in rat brain extracts.
RESULTS AND DISCUSION
Hh proteins are a family of secreted proteins, including the mammal homologue Sonic hedgehog (SHH), which regulates multiple developmental processes in specifi c tissues (Ingham and McMahon, 2001, Riobo and Manning, 2007) . Genetic analysis in Drosophila embryos has demonstrated that heparan sulphate proteoglycans (HSPG) are important players in the regulation of Hh diffusion and signaling. On the cell surface, lipidated SHh monomers are organized into oligomers that are recruited to preexisting HSPG-rich membrane domains to form large visible freely diffusible multimeric clusters (Dierker et al 2009) .
We have previously shown that in trunk explants obtained from rat embryos SHh interacts preferentially with two HSPGs, that based on its molecular weight could correspond to glypican and perlecan (Carrasco et al., 2005) . In the present study we directly evaluated the role of perlecan in SHH function.
First we analyzed the interaction between perlecan and SHh. 10T1/2 fi broblasts, which are responsive to SHh signaling, were lysed and incubated overnight either with a control or SHh-Fc resin and the fraction bound to the resin afterwards was analyzed by immunoblot with anti-perlecan antibody. We found that SHh interacts with perlecan in mouse fi broblast extract since a band that matches the expected size was pulled down and recognized by the anti-perlecan antibody ( Figure 1A ). To demonstrate the interaction of SHh with perlecan under more physiological conditions, brain extracts from E13.5 rat embryos were incubated with anti-SHh specifi c antibodies (5E1) and the complexes formed were precipitated with protein A agarose beads. The immunoprecipitates were incubated with heparitinase and then separated in SDS-PAGE and developed with antibodies against perlecan (upper panel) and SHh (lower panel). Importantly, perlecan and SHh were co-immunoprecipitated ( Figure 1B ), indicating that perlecan and SHh interact in vivo during brain development. These bands were only precipitated when the anti-SHH antibody was present indicating that the interaction was specifi c. From these results we conclude that SHh and perlecan interact biochemically.
Since we previously showed that abrogating all HSPG action by using chlorate treatment resulted in a decrease in SHh binding and signaling (see Carrasco et al., 2005) we decided to establish the particular role of perlecan in SHh localization and activity. To test this we used perlecan null mouse embryonic fibroblasts (Costell et al., 1999) . We verifi ed the absence of perlecan in these cells by PCR, immunofluorescence (data not shown) and immunoblots with anti-perlecan and anti-stub specifi c antibodies ( Figure   2A ). These analyses confi rmed that the absence of perlecan is specifi c.
We reasoned that the ability of perlecan to bind SHh might regulate its cellular localization. To test this, we made use of the monoclonal anti-SHh 5E1 antibody that is commonly used to detect the biologically active morphogen. SHh was expressed in wild-type cells independently of previous incubation with TX-100 0.1% ( Figure 2B ). Strikingly, no SHh protein was detected in perlecan null cells treated with detergent but its expression was normal in non-treated cells. This effect on SHh was not due defective expression of SHh (data not shown) or a general defect on cell-surface proteins, as Ptc1 localization was not affected in perlecan null cell ( Figure  2B ). Following this, we measured the binding of a SHh-alkaline phosphatase fusion protein (SHH-AP) to wild type and perlecan null cells. We found that in the absence of perlecan SHh-AP binds less effi ciently to the cell surface ( Figure 2C ). In summary, we have found that perlecan is required to retain SHh associated with the cell.
Figure 1. Perlecan interacts with SHH:
A) 10T1/2 cells were lysed and incubated overnight with SHh-Fc (protein-A coupled) and control resins (only protein-A) at 4ºC. The fraction bound to the resin was treated with heparitinase and analyzed by immunoblot with anti-perlecan antibody. B) Anti-SHh antibody (5E1) was crosslinked to protein-A resin and this column was incubated with E13.5 rat brain extracts. Column eluates were treated with heparitinase and loaded for immunoblot with anti-perlecan (upper gel) and anti-SHh antibody (lower gel). Bands between 170-300 kDa in 5E1 eluates correspond to perlecan, indicating that it coimmunoprecipites with SHh.
To study the role of perlecan in SHh activity, we measured AP induction and made use of a well-described SHh specifi c luciferase reporter (pGli-luc) assay. We found that SHh was not able to induce any of these targets in perlecan null cells ( Figure 3A,B) . Nevertheless perlecan -/-cells can still respond to Hh signaling since after co-transfection with a Gli2 expression construct (the main downstream activator in mice) we were able to observe pGli-luc induction, although this response was diminished ( Figure 3C ).
Our observations suggest perlecan is a strong regulator of SHh function, particularly in the brain ( Figure 1B) . Recent fi ndings indicate that SHh-proteoglycan interactions mediated by the Cardin-Weinstraub motif are specifically required for growth regulation, but not for patterning activities in the embryonic brain (Chan et al., 2009) . We have previously documented that SHh pathway activities increase presumptive stem cell and/or progenitor cells number by stimulating their proliferation and/or maintenance both in the developing dorsal brain, as well as in neurogenic niches in the adult (Palma and Ruiz i Altaba, 2004; Palma et al., 2005) . Of note, the perlecan null dorsal brain phenotype resembles the one described for SHh ko and gli2 ko (Giros et al., 2007; Palma and Ruiz i Altaba, 2004) . Thus, our analysis on the role of perlecan in SHh activity presented here suggests strongly that this HSPG is required for both localization and active signaling. We speculate that extracellular matrix composition of biological stem cell "niches" may play an important role in controlling context dependent SHh function in the CNS. 
Concluding remarks
The complexity of Hh signaling is daunting and key mechanistic questions are currently those of Hh presentation and transduction. Our fi ndings show that SHh interacts with perlecan in both cell and rat brain extracts. Perlecan is not only necessary for proper localization of SHh in fi broblasts since our experiments with perlecan ko cells further demonstrate that perlecan is required for maximal SHh signaling.
Taken together, the results of our expression, inhibition, and biochemical studies link perlecan expression and function to SHH-Gli pathway activity in both SHh responding cell lines and in the developing brain.
MATERIAL AND METHODS

Preparation of PG enriched rat brain extracts
Brains from rat E13.5 embryos were homogenized in buffer A (10 mM Tris pH 7.5, 150 mM NaCl, 0.5% TX-100 and protease inhibitors) and bound to anti-5E1 affinity columns. After binding overnight at 4ºC the beads were washed extensively with the same buffer A and treated with heparitinase (overnight at 37ºC), after that beads were eluted and loaded in SDS-PAGE for western blot analysis. The antiSHh immunoaffi nity column was prepared by coupling the 5E1 monoclonal antibody to Affi Gel 10 (Pepinsky et al., 1998; Taipale et al., 2000) .
Protein purifi cation and chromatography
SHh-Np was purified by immunoaffinity chromatography from a human 293T cell line that express mouse SHh. SHHFc was collected from conditioned media of a 293T cell line that express SHh-Fc and s-Fc from a S2 Drosophila cell line and both were purifi ed as described (Larraín et al., 2003) . For preparation of affi nity columns pure SHH-Fc and s-Fc proteins were bound to protein-A agarose beads and crosslinked using dimethylpimelimidate (DMS) (Larraín et al., 2003) . PGs enriched pools were incubated with SHH-Fc or s-Fc columns at 4ºC for 16 h with rocking, then the beads were washed with buffer A containing 0.2M or 0.5M NaCl until the radioactivity in the washout was cero and eluted with 3 column volumes of buffer A containing 1M NaCl. The eluates were dialyzed against buffer A and treated with 0.5 mU of heparitinase (Seikagaku, Japan). The samples were separated by SDS-PAGE on a 4-15% gradient gel and analyzed by Western blot using an anti-∆-heparan sulfate antibody.
Cell surface binding
Wt or perlecan -/-fi broblasts were grown to 80% confl uence in 96-well plates, washed twice with 0.2 ml of ice-cold HBSS (Hank's Balanced Salt Solution containing BSA, 0.5 mg/ml, and 20 mM Hepes, pH 7.0) and incubated for 2 h on ice with 50 μl alkaline phosphatase (AP) fusion proteins. Cells were then washed on ice 6 times with 0.2 ml of ice-cold HBSS and extracted with 60 μl of 10 mM Tris-HCl pH 7.5 containing 1% Triton X-100. Endogenous AP activity was inactivated by incubation of the plate at 65ºC for 1 h. AP activity resulting from fusion proteins bound to the cells was detected by a colorimetric AP assay. After 30 min. of incubation at 37 ºC, Confl uent wt and perlecan -/-cells were incubated with SHH 5 nM in 96-well plates for 3 days and lysed. Alkaline phosphatase (AP) activity and protein concentration were determined in cell extracts and ratio plotted. Perlecan -/-cells have no SHh-induced AP activity respect to wt cells, indicating that this proteoglycan is necessary for SHh signa ling. B) Wt and perlecan -/-cells were transfected with SHH luciferase reporter (pGLi-luc) and control plasmid (pRL) and incubated with different concentration of SHH for 1 day. Cells were lysed and luminiscence determined. SHH induced pGli-luc in wt cells, but not in perlecan -/-cells. C) Wt and perlecan -/-cells were co-transfected with the SHH reporter pGLiluc and DNA for Gli2 and luminiscence was determined. Results indicate that perlecan -/-is still able to respond to Gli. Wt, wild type; per -/-, perlecan null.
the reaction was stopped with 200 μl of 0.5 M glycine-NaOH. Absorbance was read at 405 nm in a plate reader.
Alkaline phosphatase induction
SHH activity was tested measuring alkaline phosphatase induction in wt and perlecan -/-fi broblasts based on Pepinsky et al., 1998 . Cell were plated in 96-well plates and grown to confl uence, SHh-Np or SHHN was added to the growth medium and alkaline phosphatase was measured as described after three days (Nakamura et al., 1997) . In the experiment where the effect of the peptide was tested, fresh peptide and SHh-Np were added every day.
RT-PCR and Immunofl uorescence
Samples from the perlecan defi cient and wild type controls were processed for both RT-PCR and immunofl uorescence. RNA preparation and RT-PCR conditions and sequences for the Hprt, Gli1 and SHh primer pairs were as described (Palma and Ruiz i Altaba, 2004) . Primary antibodies used were: antiperlecan domain II, anti-SHh 5E1 (1/50, Hybridoma Bank), anti-Ptc1 (1/100, Santa Cruz).
Statistics
All probability values were obtained using the Student's t-test.
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